FDA Places Partial Clinical Hold on MacroGenics' Phase 2 LINNET Study Following Patient Death
MGNX sits 44% above its 52-week low of $0.99 on light trading volume (0.3× avg).
Summary
The FDA has placed a partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab due to serious safety events, including a patient death, halting new patient enrollment.
Key Events · Product Development and Regulatory · MGNX
-
Partial Clinical Hold Issued
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Phase 2 LINNET study of lorigerlimab.
-
Enrollment Halted
No new patients will be enrolled in the LINNET study until the partial hold is lifted by the FDA, though current participants may continue to receive the study drug.
-
Serious Safety Events Reported
The hold was initiated following the company's notification of a temporary pause in enrollment due to recent safety events, including Grade 4 thrombocytopenia (N=2), Grade 4 myocarditis (N=1), and Grade 4 neutropenia with concurrent septic shock (N=1), which led to a Grade 5 (fatal) event.
-
Impact on Pipeline
This setback significantly impacts the development timeline and future prospects for lorigerlimab, an investigational bispecific DART® molecule targeting PD-1 and CTLA-4 for gynecologic cancers.
Analysis · MGNX · Life Sciences
The FDA's partial clinical hold on the Phase 2 LINNET study for lorigerlimab is a significant negative development for MacroGenics. The halt in new patient enrollment, triggered by serious safety events including a Grade 5 (fatal) event, directly impacts the development timeline and commercial prospects of this investigational bispecific molecule. For a clinical-stage biopharmaceutical company, a setback of this magnitude in a mid-stage trial can severely undermine investor confidence and necessitate a re-evaluation of the drug candidate's viability and the company's pipeline strategy. Investors should monitor updates regarding the resolution of the clinical hold and any potential changes to the study protocol or future development plans.
At the time of this filing, MGNX was trading at $1.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $110.7M. The 52-week trading range was $0.99 to $2.93. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.